open access

Vol 27, No 4 (2020)
Editorial
Published online: 2020-09-10
Get Citation

ISCHEMIA trial: The long-awaited evidence to confirm our prejudices

Carlos Cortés, Thomas W. Johnson, Sigmund Silber, Piotr P. Buszman, Tudor C. Poerner, Francesco Lavarra, Borja Ibáñez, Yongcheol Kim, Karl Mischke, Miłosz Jaguszewski, Juan Luis Gutiérrez-Chico
DOI: 10.5603/CJ.2020.0109
·
Pubmed: 32929701
·
Cardiol J 2020;27(4):336-341.

open access

Vol 27, No 4 (2020)
Editorial
Published online: 2020-09-10

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

ISCHEMIA trial: The long-awaited evidence to confirm our prejudices

Journal

Cardiology Journal

Issue

Vol 27, No 4 (2020)

Article type

Editorial

Pages

336-341

Published online

2020-09-10

DOI

10.5603/CJ.2020.0109

Pubmed

32929701

Bibliographic record

Cardiol J 2020;27(4):336-341.

Authors

Carlos Cortés
Thomas W. Johnson
Sigmund Silber
Piotr P. Buszman
Tudor C. Poerner
Francesco Lavarra
Borja Ibáñez
Yongcheol Kim
Karl Mischke
Miłosz Jaguszewski
Juan Luis Gutiérrez-Chico

References (22)
  1. Maron D, Hochman J, Reynolds H, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020; 382(15): 1395–1407.
  2. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41: 407–477.
  3. Machiavelli, Niccolò, 1469-1527. The prince. Reprinted with revisions 1984. Harmondsworth, Eng.; New York, NY: Penguin Books; 1981.Available at: https://search.library.wisc.edu/catalog/999715970702121.
  4. Maron DJ, Hochman JS, O'Brien SM, et al. ISCHEMIA Trial Research Group. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018; 201: 124–135.
  5. Hochman JS, Reynolds HR, Bangalore S, et al. ISCHEMIA Research Group. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiol. 2019; 4(3): 273–286.
  6. Spertus JA, Jones PG, Maron DJ, et al. ISCHEMIA Research Group. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N Engl J Med. 2020; 382(15): 1408–1419.
  7. Gutiérrez-Chico JL, Louvard Y. DECISION-CTO: A "negative" clinical trial? Really? Cardiol J. 2017; 24(3): 231–233.
  8. Bangalore S, Maron D, Stone G, et al. Routine revascularization versus initial medical therapy for stable ischemic heart disease: a systematic review and meta-analysis of randomized trials. Circulation. 2020.
  9. Werner GS, Martin-Yuste V, Hildick-Smith D, et al. EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018; 39(26): 2484–2493.
  10. Lee SW, Lee PH, Ahn JM, et al. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion. Circulation. 2019; 139(14): 1674–1683.
  11. Toth GG, Toth B, Johnson NP, et al. Revascularization decisions in patients with stable angina and intermediate lesions: results of the international survey on interventional strategy. Circ Cardiovasc Interv. 2014; 7(6): 751–759.
  12. Tonino PAL, De Bruyne B, Pijls NHJ, et al. FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009; 360(3): 213–224.
  13. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40: 87–165.
  14. De Bruyne B, Pijls NHJ, Kalesan B, et al. FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012; 367(11): 991–1001.
  15. Jaguszewski M, Zabalza Cerdeiriña M, Alushi B, et al. How should I treat recurrent chest pain and systolic dysfunction after chemotherapy with anthracyclines? EuroIntervention. 2017; 12(13): 1674–1677.
  16. Gutiérrez-Chico JL, Zhao S, Chatzizisis YS. Vorticity: At the crossroads of coronary biomechanics and physiology. Atherosclerosis. 2018; 273: 115–116.
  17. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356: 1503–1516.
  18. Härle T, Zeymer U, Hochadel M, et al. Real-world use of fractional flow reserve in Germany: results of the prospective ALKK coronary angiography and PCI registry. Clin Res Cardiol. 2017; 106(2): 140–150.
  19. Lee HS, Lee JM, Nam CW, et al. Consensus document for invasive coronary physiologic assessment in Asia-Pacific countries. Cardiol J. 2019; 26(3): 215–225.
  20. Sleight P. Debate: Subgroup analyses in clinical trials: fun to look at - but don’t believe them! Curr Control Trials Cardiovasc Med. 2000; 1(1): 25–27.
  21. Figulla HR, Lauten A, Maier LS, et al. Percutaneous Coronary Intervention in Stable Coronary Heart Disease -Is Less More? Dtsch Arztebl Int. 2020; 117(9): 137–144.
  22. Gutiérrez-Chico JL, Chen Y, Yu W, et al. Diagnostic accuracy and reproducibility of optical flow ratio for functional evaluation of coronary stenosis in a prospective series. Cardiol J. 2020 [Epub ahead of print].

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl